Gökhan UÇAR, Tülay EREN, Yakup ERGÜN, Ozan YAZICI, Doğan UNCU, Mustafa Özdemir, Erdal BOSTANCI, NURİYE ÖZDEMİR

Neoadjuvan Kemoterapi Alan Lokal İleri Mide Kanserli Hastalarda Primer Tümör Lokalizasyonunun Önemi

Giriş: Gastrik kanserler altıncı en sık görülen ve üçüncü en çok kansere bağlı ölüm nedenidir. 2018 yılında tüm kanserler içinde 1,033.701 (%5,7) vaka görülürken, tüm kanserler içinde 782,685 (%8,2) kansere bağlı ölüm görülmektedir. Çalışmamızda neoadjuvan kemoterapi alan lokal ileri mide adenokarsinomlu hastalarda primer tümör lokalizasyonunun prognostik önemini değerlendirmeyi amaçladık.Yöntemler: Toplam 90 hasta verisi değerlendirmeye uygun bulundu. Hastalar primer tümör lokalizasyonuna göre kardiya ve kardiya dışı olarak iki gruba ayrıldı. Gruplar hastalıksız sağkalım (HSK) ve genel sağkalım (GSK) açısından değerlendirildi.Bulgular: Medyan HSK, kardiya grubunda 34,9 ay iken kardiya dışı grubunda 11,3 ay olarak saptandı. Bu değer istatistiksel olarak anlamlıydı(34.9 vs 11.3 ay, p=0.008). Medyan GSK’da kardiya grubunda analiz esnasında henüz ulaşılamamışken, kardiya dışı grubunda ise 21.7 ay olarak saptandı. Bu değer de istatistiksel olarak anlamlı idi (NR vs 21.7 ay, p

The Importance of Primer Tumor Localization in Patıents With Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy

Objective: Gastric cancer is the sixth most common and third most common cause of cancer death. While 1,033,701 (5.7%) cases were seen among all cancers in 2018, 782,685 (8.2%) deaths due to cancer were observed among all cancers. In our study, we aimed to evaluate the prognostic significance of primary tumor localization in patients with locally advanced gastric adenocarcinoma receiving neoadjuvant chemotherapy. Methods: A total of 90 patient data were found suitable for evaluation. The patients were divided into two groups as cardia and non-cardia according to the primary tumor location. Groups were evaluated in terms of disease-free survival (DFS) and overall survival (OS). Results: The median DFS was 34.9 months in the cardia group and 11.3 months in the non-cardia group. This value was statistically significant. (34.9 vs 11.3 months, p = 0.008). While the median OS was not reached at the time of analysis in the cardia group, it was 21.7 months in the non-cardia group. This value was also statistically significant. (NR vs 21.7 months, p

PDF

___

1.Bray F, Ferlay J, Soerjomataram I, et al. Globalcancer statistics 2018: GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in185 countries. CA Cancer J Clin. 2018; 68: 394-424.
2.Waldum HL, Fossmark R. Types of GastricCarcinomas. Int J Mol Sci. 2018; 19: 4109.
3.Rawla P, Barsouk A. Epidemiology of gastriccancer: global trends, risk factor sand prevention.Prz Gastroenterol. 2019; 14: 26-38.
4. D'Ugo D, Persiani R, Zoccali M, et al. Surgical issuesafter neoadjuvant treatment for gastric cancer. EurRev Med Pharmacol Sci. 2010; 14: 315-9.
5.Zinner MJ, Ashley SW. Maingots AbdominalOperations, 12th ed. London, Mc Graw HillProfessional, 2012: 463-89.
6.Lagergren F, Xie SH, Mattsson F, Lagergren J.Updatedincidence trends in cardia and non-cardiagastric adenocarcinoma in Sweden. Acta Oncol.2018; 57: 1173-8.
7. Jeon J, Luebeck EG, Moolgavkar SH. Age effects andtempora ltrends in adenocarcinoma oftheesophagus and gastric cardia (United States).Cancer Causes Control. 2006; 17: 971-81.
8.Brown LM, Devesa SS. Epidemiologic trends inesophageal and gastric cancer in the United States.Surg Oncol Clin N Am. 2002; 11: 235-56.
9.Wilke H, Preusser P, Fink U, et al. Preoperativechemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide,doxorubicin, and cisplatin. J Clin Oncol. 1989 Sep;7:1318-26.
10.Hu N, Wang Z, Song X, et al. Genome-wideassociation study of gastric adenocarcinoma in Asia:a comparison of associations between cardia andnon-cardia tumours. Gut. 2016; 65: 1611-8.
11.Bruno L, Nesi G, Montinaro F, et al.Clinicopathologic findings and results of surgicaltreatment in cardia cadenocarcinoma. J Surg Oncol.2000; 74: 33-5.
12.Park JC, Lee YC, Kim JH, et al. Clinicopathologic alfeatures and prognostic factors of proximal gastriccarcinoma in a population withhigh Helicobacterpylori prevalence: a single-center, large-volumestudy in Korea. Ann Surg Oncol. 2010; 17: 829-37.
13.Piso P, Werner U, Lang H, Mirena P, KlempnauerJ.Proximal versus distal gastric carcinoma—whatare the differences? Ann Surg Oncol. 2000; 7: 520-5.
14.Zhao J, Zhao J, Du F, et al. Cardiaand Non-CardiaGastric Cancer Have Similar Stage-for-StagePrognoses After R0 Resection: a Large-Scale,Multicenter Study in China. J Gastrointest Surg.2016; 20: 700-7.
15.Mariette C, Castel B, Toursel H, et al. Surgicalmanagement of andlong-termsurvival afteradenocarcinoma of thecardia. Br J Surg. 2002; 89:1156-63.
16.Colquhoun A, Arnold M, Ferlay J, et al. Globalpatterns of cardia and non-cardia gastric cancerincidence in 2012. Gut. 2015; 64: 1881-88.
17.American Cancer Society. Stomach CancerSurvival Rates. 2020. (09/09/2020 tarahindehttps://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html#references adresinden ulaşılmıştır).
18.Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgeryaloneforresec table gastroes ophageal cancer. NEngl J Med. 2006; 355: 11-20.
19.Cancer Genome Atlas Research Network.Comprehensive molecular characterization ofgastric adenocarcinoma. Nature. 2014; 513: 202-9.
20. Pirhan Y. Analysis of Prognostic Factors AffectingPostoperative Survival in Stage III Gastric CancerPatients. Dicle Med J. 2020; 47: 34-42.